Humacyte Inc. is a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale. Humacyte Inc., formerly known as Alpha Healthcare Acquisition Corp., is based in DURHAM, N.C.
| Revenue (Most Recent Fiscal Year) | $1.57M |
| Net Income (Most Recent Fiscal Year) | $-148.70M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -2353.22% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -68.85% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.62 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.90 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 2.97 |
| Inventory Turnover (Trailing 12 Months) | 0.07 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.41 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.14 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.05 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.23 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 187.27M |
| Free Float | 177.72M |
| Market Capitalization | $241.58M |
| Average Volume (Last 20 Days) | 4.79M |
| Beta (Past 60 Months) | 1.90 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 5.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 44.71% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |